Allergic Rhinitis Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled Study to Determine Safety, Tolerability and the Optimal Effective Dose of SUBLIVAC FIX Phleum Pratense in Patients With Allergic Rhinitis/Rhinoconjunctivitis Caused by Grass Pollen
The aim of the study is to determine the optimal effective dose of SUBLIVAC FIX Phleum pratense based on reduction of upper airways reactivity after 5 months of treatment with different dosages of SUBLIVAC FIX Phleum pratense compared to placebo. Furthermore, safety and tolerability will be assessed by the number of related Adverse Events of different dosages of SUBLIVAC FIX Phleum pratense compared to placebo.
Status | Completed |
Enrollment | 266 |
Est. completion date | May 2013 |
Est. primary completion date | May 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Signed informed consent - Age = 18 = 60 years - Allergic rhinitis/rhinoconjunctivitis related to grass pollen with or without concomitant mild to moderate persistent asthma - FEV1 > 70% for patients with a history of asthma, FEV > 70% or PEF > 80% for patients without a history of asthma - A positive SPT (mean wheal diameter = 3mm compared to negative control and negative control should be negative) for grass pollen assessed within 1 year before randomization. - Positive serum specific anti-grass IgE-test (> 0.7 U/mL) - A positive TNPT for grass pollen at screening (Lebel score = 6) at =10,000 AU/mL Exclusion Criteria: - Patients with (expected) clinically relevant symptoms during the course of the trial due to concomitant sensitization i.e. positive SPT (mean wheal diameter = 3mm) to allergens other than grass pollen - Patients sensitized to pets should not be included if they are regularly exposed to pets and are symptomatic upon exposure to pets - Completed immunotherapy (SCIT or SLIT) with grass pollen allergens within the past 5 years - Completed unsuccessful specific immunotherapy in the past - Vaccination within one week before start of therapy or during the initiation phase - Anti-IgE therapy within the 6 months prior to inclusion and during the study - Severe immune disorders (including auto-immune diseases) and/or diseases requiring immunosuppressive drugs - Active malignancies or any malignant disease during the previous 5 years - Severe uncontrolled diseases that could increase the risk for patients participating in the study, including but not limited to: cardiovascular insufficiency, any severe or unstable lung diseases, endocrine diseases, clinically significant renal or hepatic diseases, or haematological disorders - Active inflammation or infection of the target organs (nose, eyes or lower airways) at the start of the study - Moderate to severe nasal obstructive diseases that preclude a TNPT (septal deviation, nasal polyps, recent nasal surgery, etc.) - Diseases with a contraindication for the use of Adrenaline (e.g. hyperthyroidism, glaucoma) - Use of systemic steroids within 4 weeks before start of the study and during the study - Treatment with systemic and local ß-blockers - Participation in a clinical study with a new investigational drug within the last 3 months or for a biological within the last 6 months prior to or during the study - Pregnancy, lactation or inadequate contraceptive measures for women of child-bearing age (adequate contraceptive measures will be the use of a contraceptive device or -pill) - Alcohol, drug or medication abuse within the past year - Any clinically significant abnormal laboratory parameter at screening - Lack of cooperation or compliance - Severe psychiatric, psychological, or neurological disorders - Patients who are employees of the institution or 1st grade relatives or partners of the investigator |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | CIMS Studienzentrum Bamberg | Bamberg | |
Germany | Charité Universitaetsmedizin Berlin Klinik f. Dermatalogie, Venerologie u. Allergologie, Campus Charité Mitte | Berlin | |
Germany | Klinik u. Poliklinik f. Dermatologie u. Allergologie Universität Bonn | Bonn | |
Germany | Dermatologikum Hamburg - Dept. of Allergology | Hamburg | |
Germany | HNO Praxis Dr. Horn/Dr. Zeuner | Heidelberg | |
Germany | Klinikum der Johann-Wolfgang-Goethe Universität - Zentrum f. Kinder- u. Jugendmedizin | Hessen | |
Germany | Dres.Ina Röhrig-Petering und Holger Petering | Hildesheim | |
Germany | FÄ HNO Allergologie | Saalfeld /Saale | |
Germany | Klinikum Stuttgart - Klinik f. Dermatologie u. Allergologie | Stuttgart | |
Germany | Universitäts- Hautklinik Eberhard Karls - Universität Tübingen Department of Dermatology | Tübingen | |
Germany | Dr. Med. Ulrich Neumann | Wolmirstedt | |
Poland | Prywatna Praktyka Lekarska Gabinet Pediatryczno-Alergologiczny | Bialystok | |
Poland | SP-ZOZ Osrodek Zdrowia w Bienkówce | Bienkówka | |
Poland | NZOS "Zdrowie" | Cieszyn | |
Poland | Poradnia Alergologiczna Samodzielnego Publicznego Szpitala Nr 5 Slaskiego Uniwersytetu Medycznego w Katowicach | Katowice | |
Poland | Poradnia Alergologii i Chorób Pluc SP ZOZ Uniwersytecki Szpital Kliniczny im Norberta Barlickiego w Lodzi | Lodz | |
Poland | NZOZ Centrum Alergologii | Lódz | |
Poland | ALERGOPNEUMA Marek Michnar i Wspolnicy Sp. Jawna | Lublin | |
Poland | NZOZ Centrum Alergologii | Lublin | |
Poland | Centrum Alergologii Teresa Hofman | Poznan | |
Poland | ALERGOMED Specjalistyczna Przychodnia Lekarska Sp. z o.o. | Tarnów | |
Poland | EMC Intytut Medyczny S.A. Przychodnia przy Lowieckiej | Wroclaw | |
Poland | NZOZ Lekarze Specjalisci J. Malolepszy i Partnerzy | Wroclaw |
Lead Sponsor | Collaborator |
---|---|
HAL Allergy |
Germany, Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Nasal Provocation Test (NPT) | 5 months | No | |
Primary | Number of related AEs | First ten days of study medication intake | Yes | |
Secondary | Serum specific immunoglobulin levels (IgE, IgG, IgG4) | 5 months | No | |
Secondary | Number of local and systemic reactions | Duration of study medication intake (approximately 5 months) | Yes | |
Secondary | Peak Nasal Inspiratory Flow (PNIF) | 5 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05080322 -
Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis
|
Phase 4 | |
Recruiting |
NCT06028490 -
A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis.
|
Phase 2 | |
Completed |
NCT04388358 -
Traditional Chinese Medicine for the Treatment of Perennial Allergic Rhinitis on Gut Microbiota and Immune-modulation
|
N/A | |
Recruiting |
NCT04202263 -
Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline
|
Phase 2 | |
Completed |
NCT04078009 -
Standardising Nasal Allergen Challenge in Adult With Hay Fever
|
N/A | |
Completed |
NCT03644680 -
Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study
|
N/A | |
Completed |
NCT04541004 -
Adolescent Mite Allergy Safety Evaluation
|
Phase 3 | |
Recruiting |
NCT05378594 -
HDM and Silver Birch NAC Standardisation
|
N/A | |
Not yet recruiting |
NCT05684380 -
Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)
|
Phase 3 | |
Completed |
NCT02910401 -
Clinical Response to Rhinovirus Challenge
|
Phase 2 | |
Completed |
NCT02943720 -
ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen
|
Phase 2 | |
Not yet recruiting |
NCT01014325 -
Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy
|
Phase 3 | |
Completed |
NCT02556801 -
Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
|
Phase 2 | |
Completed |
NCT02352168 -
Airway Inflammation in Children With Allergic Rhinitis and Intervention
|
N/A | |
Not yet recruiting |
NCT02233426 -
Effect of Hypertonic Solutions on Allergic Rhinitis Patients
|
N/A | |
Completed |
NCT01946035 -
Alpha-Blockers in Allergic Rhinitis (MAN 01)
|
Phase 4 | |
Completed |
NCT01918956 -
PURETHAL Birch RUSH Study
|
Phase 4 | |
Recruiting |
NCT01454492 -
The Relationship Between Allergic Rhinitis and Geographic Tongue
|
N/A | |
Completed |
NCT01439815 -
An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo
|
Phase 4 | |
Completed |
NCT01438463 -
PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis
|
Phase 2 |